In patients with relapsing-remitting multiple sclerosis (MS), certain disease-modifying therapies (DMTs) may be more associated with serious infections than others, according to an observational study from Sweden.
New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A pooled analysis of two large-scale randomized clinical trials demonstrated that the significant secondary prevention benefit of dual antiplatelet therapy was confined to the first 21 days of administering clopidogrel-aspirin following minor ischaemic stroke or high-risk transient ischaemic attack (TIA).
A study of 74 Swedish twins and triplets discordant for attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and other neurodevelopmental diagnoses identified a consistent reduction in regularity and complexity of cobalt, lead and vanadium cycles in individuals with ADHD.
New drug applications approved by US FDA as of 16 - 30 September 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
An aerobic physical fitness training in adults with moderate-to-severe subacute stroke is not better than relaxation intervention in terms of maximal walking speed and activities of daily living (ADL), a new study has shown. The risk of falls is also higher in participants undergoing physical fitness training.
Specific functional network-based moderators of treatment outcome have been identified, and these involve brain networks affected by major depression, reports a study. In addition, a favourable response for an antidepressant medication appears to be influenced by functional connectivity patterns of brain regions between and within networks.